A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2, in The European Association for the Study of the Liver (EASL) 50th Annual Meeting 2015 - Lawitz, E
et al.